One Health approach
Submitted by Anonymous (not verified) on 19 January 2026 - 9:35
One Health approach
Human medicines European public assessment report (EPAR): Aprovel, irbesartan, Date of authorisation: 26/08/1997, Revision: 51, Status: Authorised
Submitted by Anonymous (not verified) on 19 January 2026 - 9:15
Human medicines European public assessment report (EPAR): Aprovel, irbesartan, Date of authorisation: 26/08/1997, Revision: 51, Status: Authorised
Agenda of the HMPC meeting 19-21 January 2026
Submitted by Anonymous (not verified) on 19 January 2026 - 7:31
Agenda of the HMPC meeting 19-21 January 2026
European Shortages Monitoring Platform (ESMP)
Submitted by Anonymous (not verified) on 16 January 2026 - 22:18
European Shortages Monitoring Platform (ESMP)
Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 9, Status: Authorised
Submitted by Anonymous (not verified) on 16 January 2026 - 16:42
Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Namuscla, mexiletine hcl, Date of authorisation: 18/12/2018, Revision: 8, Status: Authorised
Submitted by Anonymous (not verified) on 16 January 2026 - 16:00
Human medicines European public assessment report (EPAR): Namuscla, mexiletine hcl, Date of authorisation: 18/12/2018, Revision: 8, Status: Authorised
PSUSA/00000411/202505
Submitted by Anonymous (not verified) on 16 January 2026 - 15:49
PSUSA/00000411/202505
PSUSA/00010226/202505
Submitted by Anonymous (not verified) on 16 January 2026 - 15:47
PSUSA/00010226/202505
PSUSA/00001128/202505
Submitted by Anonymous (not verified) on 16 January 2026 - 15:46
PSUSA/00001128/202505
PSUSA/00010651/202505
Submitted by Anonymous (not verified) on 16 January 2026 - 15:45
PSUSA/00010651/202505